EP3887509A4 - Récepteur d'antigène chimère et procédés d'utilisation de celui-ci - Google Patents
Récepteur d'antigène chimère et procédés d'utilisation de celui-ci Download PDFInfo
- Publication number
- EP3887509A4 EP3887509A4 EP19889550.0A EP19889550A EP3887509A4 EP 3887509 A4 EP3887509 A4 EP 3887509A4 EP 19889550 A EP19889550 A EP 19889550A EP 3887509 A4 EP3887509 A4 EP 3887509A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- factories
- methods
- antigen receptor
- chimeric antigen
- chimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/56—Kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773885P | 2018-11-30 | 2018-11-30 | |
US201962826462P | 2019-03-29 | 2019-03-29 | |
PCT/US2019/064032 WO2020113224A2 (fr) | 2018-11-30 | 2019-12-02 | Récepteur d'antigène chimère et procédés d'utilisation de celui-ci |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3887509A2 EP3887509A2 (fr) | 2021-10-06 |
EP3887509A4 true EP3887509A4 (fr) | 2022-08-31 |
Family
ID=70853578
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19889550.0A Pending EP3887509A4 (fr) | 2018-11-30 | 2019-12-02 | Récepteur d'antigène chimère et procédés d'utilisation de celui-ci |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220047634A1 (fr) |
EP (1) | EP3887509A4 (fr) |
JP (1) | JP2022513668A (fr) |
KR (1) | KR20210135475A (fr) |
AU (1) | AU2019387566A1 (fr) |
CA (1) | CA3119644A1 (fr) |
WO (1) | WO2020113224A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3038504A1 (fr) * | 2016-10-14 | 2018-04-19 | Dana-Farber Cancer Institute, Inc. | Plate-forme d'anticorps bispecifique tetramere modulaire |
CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
CA3141628A1 (fr) * | 2019-06-14 | 2020-12-17 | Dana-Farber Cancer Institute, Inc. | Anticorps diriges contre pdl1 et procedes d'utilisation associes |
AU2020291946A1 (en) * | 2019-06-14 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
CN114565761B (zh) * | 2022-02-25 | 2023-01-17 | 无锡市第二人民医院 | 一种基于深度学习的肾透明细胞癌病理图像肿瘤区域的分割方法 |
WO2023235933A1 (fr) * | 2022-06-09 | 2023-12-14 | Telix Pharmaceuticals (Innovations) Pty Ltd | Polythérapie |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013123061A1 (fr) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
WO2017075537A1 (fr) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions et méthodes pour le du traitement du cancer |
WO2018152181A1 (fr) * | 2017-02-14 | 2018-08-23 | Kite Pharma, Inc. | Molécules de liaison à cd70 et leurs procédés d'utilisation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2686347T1 (en) * | 2011-03-16 | 2018-08-31 | Argenx Bvba | Antibodies against CD70 |
CN108064251A (zh) * | 2014-12-19 | 2018-05-22 | 达纳-法伯癌症研究所公司 | 碳酸酐酶ix特异性嵌合抗原受体及其使用方法 |
WO2016149578A1 (fr) * | 2015-03-19 | 2016-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs doubles spécifiques de l'antigène chimère anti-cd22-anti-cd19 |
US20190031759A1 (en) * | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
JP2020508663A (ja) * | 2017-02-22 | 2020-03-26 | アレタ・バイオセラピューティクス・インコーポレイテッドAleta Biotherapeutics Inc. | 癌の治療のための組成物及び方法 |
-
2019
- 2019-01-12 US US17/298,271 patent/US20220047634A1/en active Pending
- 2019-12-02 WO PCT/US2019/064032 patent/WO2020113224A2/fr unknown
- 2019-12-02 JP JP2021530875A patent/JP2022513668A/ja active Pending
- 2019-12-02 CA CA3119644A patent/CA3119644A1/fr active Pending
- 2019-12-02 KR KR1020217019851A patent/KR20210135475A/ko active Search and Examination
- 2019-12-02 EP EP19889550.0A patent/EP3887509A4/fr active Pending
- 2019-12-02 AU AU2019387566A patent/AU2019387566A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013123061A1 (fr) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci |
WO2017075537A1 (fr) * | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions et méthodes pour le du traitement du cancer |
WO2018152181A1 (fr) * | 2017-02-14 | 2018-08-23 | Kite Pharma, Inc. | Molécules de liaison à cd70 et leurs procédés d'utilisation |
Non-Patent Citations (1)
Title |
---|
ADAM P J ET AL: "CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP UK, LONDON, vol. 95, no. 3, 7 August 2006 (2006-08-07), pages 298 - 306, XP002440598, ISSN: 0007-0920, DOI: 10.1038/SJ.BJC.6603222 * |
Also Published As
Publication number | Publication date |
---|---|
JP2022513668A (ja) | 2022-02-09 |
EP3887509A2 (fr) | 2021-10-06 |
WO2020113224A3 (fr) | 2020-08-20 |
CA3119644A1 (fr) | 2020-06-04 |
WO2020113224A2 (fr) | 2020-06-04 |
US20220047634A1 (en) | 2022-02-17 |
AU2019387566A1 (en) | 2021-06-17 |
KR20210135475A (ko) | 2021-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3564266A4 (fr) | Nouveau récepteur chimère de l'antigène et utilisation correspondante | |
EP3579877A4 (fr) | Récepteurs antigéniques de lymphocytes t chimériques et leurs procédés d'utilisation | |
EP3887509A4 (fr) | Récepteur d'antigène chimère et procédés d'utilisation de celui-ci | |
EP3436079A4 (fr) | Récepteurs antigéniques chimériques et récepteurs de lymphocytes t et leurs procédés d'utilisation | |
EP3732191A4 (fr) | Récepteurs antigéniques chimériques améliorés et leurs utilisations | |
EP3658163A4 (fr) | Récepteurs antigéniques chimériques améliorés et leurs utilisations | |
EP3334765A4 (fr) | Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation | |
EP3645574A4 (fr) | Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation | |
EP3820484A4 (fr) | Récepteurs antigéniques chimériques specifiques de ror-1 et utilisations associées | |
EP3261650A4 (fr) | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs | |
EP3665270A4 (fr) | Lymphocytes t récepteurs d'antigènes chimériques déficients en récepteurs de lymphocyte t et procédés d'utilisation correspondants | |
IL283734A (en) | Chimeric antigen receptors and car-t cells and methods of use | |
EP3827025A4 (fr) | Récepteur antigénique chimérique à base de gd2 et utilisation associée | |
EP3852805A4 (fr) | Anticorps anti-lilrb2 et leurs méthodes d'utilisation | |
EP3812401A4 (fr) | Récepteur antigénique chimérique comprenant un troisième récepteur de signal et utilisation associée | |
IL276790A (en) | b7-h4 antibodies and methods of using them | |
EP3919515A4 (fr) | Récepteur d'antigène chimère et utilisation correspondante | |
EP3515493A4 (fr) | Récepteurs d'antigènes chimériques, compositions et procédés d'utilisation coorespondants | |
EP3728323A4 (fr) | Anticorps anti-fzd et méthodes d'utilisation | |
EP3684819A4 (fr) | Anticorps anti-ykl40 et méthodes d'utilisation | |
EP3873939A4 (fr) | Anticorps anti-cd79b et récepteurs d'antigènes chimériques et leurs procédés d'utilisation | |
EP3802615A4 (fr) | Récepteurs antigéniques chimériquesspecifiques de muc16 et utilisations associées | |
EP3765078A4 (fr) | Compositions à base d'un récepteur antigénique chimérique anti-gucy2c et méthodes | |
EP3710589A4 (fr) | Anticorps anti-c1s et procédés d'utilisation | |
EP3720481A4 (fr) | Anticorps anti-dclk1 et récepteurs antigéniques chimériques et compositions et procédés d'utilisation correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210521 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220729 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/30 20060101ALI20220725BHEP Ipc: C07K 14/725 20060101ALI20220725BHEP Ipc: A61K 39/00 20060101ALI20220725BHEP Ipc: A61P 35/00 20060101ALI20220725BHEP Ipc: C07K 19/00 20060101ALI20220725BHEP Ipc: C07K 16/28 20060101ALI20220725BHEP Ipc: C12N 5/09 20100101ALI20220725BHEP Ipc: C12N 5/0783 20100101AFI20220725BHEP |